EVE-SENSE
17.3.2021 03:02:06 CET | Business Wire | Press release
Eve-sense Inc. (President and CEO: Kousuke Shimizu; hereafter, “Eve-sense”) is pleased to present information on “Casino Station – Global Ranking”, along with the start of preregistration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005590/en/
Our product is a full-fledged casino game that is irresistible to casino lovers while sticking to what makes these games great. It features everything from roulette, bingo and table games to slots and dog races, and allows players to use casino coins to play regular (non-casino) games as well. Enjoy over 100 different games of chance and listen to a magnificent orchestral soundtrack while competing in the rankings with players from all over the world!
[Casino Station Official Website]
https://contents.eve-sense.com/casino-station/
[Click the link below to preregister on Google Play]
https://play.google.com/store/apps/details?id=net.ca_si_no.gamestation
[See footage of the game in action on YouTube]
https://youtu.be/SwEs_fd2feA
[Introducing the Different Categories of Games!]
Casino Station from Eve-sense features a total of 12 different types of casinos and game categories. Players will ultimately be able to experience 15 different types, including login bonuses, minigames and future titles under development.
These include poker games, slots games, table games, roulette, lotteries, racing, action games, strategy games, board games, sports games, solitaire and puzzle games.
Casino Station is a game where you're not just trying to earn more coins, but where you're also able to use those coins to enjoy different games. We're looking forward to you taking this opportunity to register with Casino Station!
https://play.google.com/store/apps/details?id=net.ca_si_no.gamestation
Important Information
Casino Station is a game.
It does not provide the opportunity for players to gamble using real money or to win real prizes. It is not implied that practicing these games in the app will translate to success in gambling with real money in the future.
Eve-sense Inc. develops planning, production and management for various information services via the Internet. |
|
Company Home Page |
|
---------------------------------------------- |
|
[Related Websites] |
|
Reiwa Marriage Agency |
|
Noah |
|
Bizcon |
|
Gigabyte Push |
|
---------------------------------------------- |
|
Company Name: Eve-sense Inc. |
|
Date Established: June 1, 2017 |
|
Representative: Kousuke Shimizu, President and CEO |
|
Type of Business: Planning, production, management and software development for various information services via the Internet |
|
---------------------------------------------- |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005590/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom